213 related items for PubMed ID: 9205761
1. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
Muñoz-Navas M, Honorato J, Reina-Ariño M, Márquez M, Herrero E, Villamayor F, Torres J, Roset PN, Fíllat O, Camps F, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
[Abstract] [Full Text] [Related]
2. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M, Kwiecień N, Obtułowicz W, Konturek SJ, Kamiński K, Oleksy J, Gabryelewicz A, Torres J.
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[Abstract] [Full Text] [Related]
3. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D, Agut J, Márquez M, Conejo L, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[Abstract] [Full Text] [Related]
4. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
Gabryelewicz A, Czajkowski A, Skrodzka D, Marlicz K, Luca de Tena F, Aldeguer M, Chantar C, Márquez M, Torres J, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
[Abstract] [Full Text] [Related]
5. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Frías J, Esteban C, Carcas AJ, Sánchez-García P, Albet C, Torres J, Márquez M, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
[Abstract] [Full Text] [Related]
6. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
Gedliczka O, Bobrzynski A, Rembiasz K, Fillat O, Torres J, Herrero E, Márquez M, Camps F, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
[Abstract] [Full Text] [Related]
7. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D, Romero A, Villamayor F, Conejo L, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[Abstract] [Full Text] [Related]
8. The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring.
Palasciano G, Maggi V, Portincasa P.
Ital J Gastroenterol; 1990 Oct; 22(5):291-4. PubMed ID: 1983712
[Abstract] [Full Text] [Related]
9. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
Farré M, Roset PN, Badenas JM, Ugena B, Márquez M, Albet C, Herrero E, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
[Abstract] [Full Text] [Related]
10. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I, Puscas C, Coltau M, Torres J, Márquez M, Herrero E, Fillat O, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[Abstract] [Full Text] [Related]
11. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
Tulassay Z, Döbrönte Z, Farkas I, Juhász L, Simon L, Prónai L, Torres J, Márquez M.
Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
[Abstract] [Full Text] [Related]
12. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC, Brzozowski T, Konturek SI, Márquez M, Torres J, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[Abstract] [Full Text] [Related]
13. Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors.
Agut J, Sánchez JC, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):447-9. PubMed ID: 9205741
[Abstract] [Full Text] [Related]
14. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A, Villamayor F, Palop D, Falcó J, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[Abstract] [Full Text] [Related]
15. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
Romero A, Gómez F, Villamayor F, Ballesta A, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):524-7. PubMed ID: 9205757
[Abstract] [Full Text] [Related]
16. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
Dammann HG, Gottlieb WR, Walter TA, Dreyer M, Müller P, Simon B, Keohane P.
Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
[Abstract] [Full Text] [Related]
17. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL, Piotrowski J, Slomiany A.
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[Abstract] [Full Text] [Related]
18. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C, Albet C, Agúndez JA, Herrero E, Carrillo JA, Márquez M, Benítez J, Ortiz JA.
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[Abstract] [Full Text] [Related]
19. Gastroprotective properties of ebrotidine. A review.
Slomiany BL, Piotrowski J, Slomiany A.
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[Abstract] [Full Text] [Related]
20. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Albet C, Pérez JA, Rozman E, Márquez M, Herrero E, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
